FDA Approval Insights: Talquetamab in Relapsed/Refractory Multiple Myeloma
0
0
0 Visninger·
09/07/23
Dr Minnema discusses the FDA approval of talquetamab in patients with relapsed/refractory multiple myeloma, key data from the MonumenTAL-1 trial, and the importance of designing clinical trials to address unmet patient needs.
Vis mere
0 Kommentarer
sort Sorter efter